| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Patrik Roser, Eva-Maria Pichler, Benedikt Habermeyer, Wolfram Kawohl, Georg Jucke. Impact of Chronic Cannabis Use on Auditory Mismatch Negativity Generation in Schizophrenia Patients. Pharmacopsychiatry. vol 52. issue 3. 2019-06-20. PMID:29506304. |
impact of chronic cannabis use on auditory mismatch negativity generation in schizophrenia patients. |
2019-06-20 |
2023-08-13 |
Not clear |
| Patrik Roser, Eva-Maria Pichler, Benedikt Habermeyer, Wolfram Kawohl, Georg Jucke. Impact of Chronic Cannabis Use on Auditory Mismatch Negativity Generation in Schizophrenia Patients. Pharmacopsychiatry. vol 52. issue 3. 2019-06-20. PMID:29506304. |
cannabis use disorders (cud) are highly prevalent among patients with schizophrenia (scz). |
2019-06-20 |
2023-08-13 |
Not clear |
| D M Coviello, R Lovato, K Apostol, M M Eisenberg, D S Metzger, R Szucs-Reed, N Kiryankova-Dalseth, D Kelly, A Jackson, M Plano, M B Blan. Prevalence of HIV Viral Load Suppression Among Psychiatric Inpatients with Comorbid Substance Use Disorders. Community mental health journal. vol 54. issue 8. 2019-06-17. PMID:29752639. |
psychiatric disorders included depression (64%), schizophrenia (21%), and bipolar disorder (13%) with patients reporting use of alcohol (73%), cocaine (64%), cannabis (29%) and opioids (16%) prior to admission. |
2019-06-17 |
2023-08-13 |
Not clear |
| Joëlle A Pasman, Karin J H Verweij, Zachary Gerring, Sven Stringer, Sandra Sanchez-Roige, Jorien L Treur, Abdel Abdellaoui, Michel G Nivard, Bart M L Baselmans, Jue-Sheng Ong, Hill F Ip, Matthijs D van der Zee, Meike Bartels, Felix R Day, Pierre Fontanillas, Sarah L Elson, Harriet de Wit, Lea K Davis, James MacKillop, Jaime L Derringer, Susan J T Branje, Catharina A Hartman, Andrew C Heath, Pol A C van Lier, Pamela A F Madden, Reedik Mägi, Wim Meeus, Grant W Montgomery, A J Oldehinkel, Zdenka Pausova, Josep A Ramos-Quiroga, Tomas Paus, Marta Ribases, Jaakko Kaprio, Marco P M Boks, Jordana T Bell, Tim D Spector, Joel Gelernter, Dorret I Boomsma, Nicholas G Martin, Stuart MacGregor, John R B Perry, Abraham A Palmer, Danielle Posthuma, Marcus R Munafò, Nathan A Gillespie, Eske M Derks, Jacqueline M Vin. GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia. Nature neuroscience. vol 21. issue 9. 2019-05-15. PMID:30150663. |
gwas of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia. |
2019-05-15 |
2023-08-13 |
Not clear |
| Joëlle A Pasman, Karin J H Verweij, Zachary Gerring, Sven Stringer, Sandra Sanchez-Roige, Jorien L Treur, Abdel Abdellaoui, Michel G Nivard, Bart M L Baselmans, Jue-Sheng Ong, Hill F Ip, Matthijs D van der Zee, Meike Bartels, Felix R Day, Pierre Fontanillas, Sarah L Elson, Harriet de Wit, Lea K Davis, James MacKillop, Jaime L Derringer, Susan J T Branje, Catharina A Hartman, Andrew C Heath, Pol A C van Lier, Pamela A F Madden, Reedik Mägi, Wim Meeus, Grant W Montgomery, A J Oldehinkel, Zdenka Pausova, Josep A Ramos-Quiroga, Tomas Paus, Marta Ribases, Jaakko Kaprio, Marco P M Boks, Jordana T Bell, Tim D Spector, Joel Gelernter, Dorret I Boomsma, Nicholas G Martin, Stuart MacGregor, John R B Perry, Abraham A Palmer, Danielle Posthuma, Marcus R Munafò, Nathan A Gillespie, Eske M Derks, Jacqueline M Vin. GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia. Nature neuroscience. vol 21. issue 9. 2019-05-15. PMID:30150663. |
mendelian randomization analysis showed evidence for a causal positive influence of schizophrenia risk on cannabis use. |
2019-05-15 |
2023-08-13 |
Not clear |
| M S Islam, M M Hasan, C R Debnath, M A Uddin, N Biswas, K M Kabir, M H Bhuiyan, M K Bakshi, M S Malek, M S Kader, K S Rahman, M J Hussai. Exceptional Multiple Foreign-Body Ingestion by a Patient with Schizophrenia. Mymensingh medical journal : MMJ. vol 26. issue 1. 2019-04-15. PMID:28260775. |
he was psychiatrically evaluated after recovery from operation and was found to be suffering from schizophrenia with cannabis use. |
2019-04-15 |
2023-08-13 |
Not clear |
| J Vaucher, B J Keating, A M Lasserre, W Gan, D M Lyall, J Ward, D J Smith, J P Pell, N Sattar, G Paré, M V Holme. Cannabis use and risk of schizophrenia: a Mendelian randomization study. Molecular psychiatry. vol 23. issue 5. 2019-03-27. PMID:28115737. |
cannabis use and risk of schizophrenia: a mendelian randomization study. |
2019-03-27 |
2023-08-13 |
Not clear |
| J Vaucher, B J Keating, A M Lasserre, W Gan, D M Lyall, J Ward, D J Smith, J P Pell, N Sattar, G Paré, M V Holme. Cannabis use and risk of schizophrenia: a Mendelian randomization study. Molecular psychiatry. vol 23. issue 5. 2019-03-27. PMID:28115737. |
using a genetic approach, we took 10 independent genetic variants previously identified to associate with cannabis use in 32 330 individuals to determine the nature of the association between cannabis use and risk of schizophrenia. |
2019-03-27 |
2023-08-13 |
Not clear |
| J Vaucher, B J Keating, A M Lasserre, W Gan, D M Lyall, J Ward, D J Smith, J P Pell, N Sattar, G Paré, M V Holme. Cannabis use and risk of schizophrenia: a Mendelian randomization study. Molecular psychiatry. vol 23. issue 5. 2019-03-27. PMID:28115737. |
genetic variants were employed as instruments to recapitulate a randomized controlled trial involving two groups (cannabis users vs nonusers) to estimate the causal effect of cannabis use on risk of schizophrenia in 34 241 cases and 45 604 controls from predominantly european descent. |
2019-03-27 |
2023-08-13 |
Not clear |
| J Vaucher, B J Keating, A M Lasserre, W Gan, D M Lyall, J Ward, D J Smith, J P Pell, N Sattar, G Paré, M V Holme. Cannabis use and risk of schizophrenia: a Mendelian randomization study. Molecular psychiatry. vol 23. issue 5. 2019-03-27. PMID:28115737. |
genetically-derived estimates were compared with a meta-analysis of observational studies reporting ever use of cannabis and risk of schizophrenia or related disorders. |
2019-03-27 |
2023-08-13 |
Not clear |
| J Vaucher, B J Keating, A M Lasserre, W Gan, D M Lyall, J Ward, D J Smith, J P Pell, N Sattar, G Paré, M V Holme. Cannabis use and risk of schizophrenia: a Mendelian randomization study. Molecular psychiatry. vol 23. issue 5. 2019-03-27. PMID:28115737. |
based on the genetic approach, use of cannabis was associated with increased risk of schizophrenia (odds ratio (or) of schizophrenia for users vs nonusers of cannabis: 1.37; 95% confidence interval (ci), 1.09-1.67; p-value=0.007). |
2019-03-27 |
2023-08-13 |
Not clear |
| J Vaucher, B J Keating, A M Lasserre, W Gan, D M Lyall, J Ward, D J Smith, J P Pell, N Sattar, G Paré, M V Holme. Cannabis use and risk of schizophrenia: a Mendelian randomization study. Molecular psychiatry. vol 23. issue 5. 2019-03-27. PMID:28115737. |
the genetic markers did not show evidence of pleiotropic effects and accounting for tobacco exposure did not alter the association (or of schizophrenia for users vs nonusers of cannabis, adjusted for ever vs never smoker: 1.41; 95% ci, 1.09-1.83). |
2019-03-27 |
2023-08-13 |
Not clear |
| Thomas Schnell, Karsten Heekeren, Jörg Daumann, Euphrosyne Gouzoulis-Mayfran. Inhibition of return (IOR) in patients with schizophrenia and cannabis use. Progress in neuro-psychopharmacology & biological psychiatry. vol 89. 2019-03-25. PMID:30184467. |
inhibition of return (ior) in patients with schizophrenia and cannabis use. |
2019-03-25 |
2023-08-13 |
human |
| Thomas Schnell, Karsten Heekeren, Jörg Daumann, Euphrosyne Gouzoulis-Mayfran. Inhibition of return (IOR) in patients with schizophrenia and cannabis use. Progress in neuro-psychopharmacology & biological psychiatry. vol 89. 2019-03-25. PMID:30184467. |
other recent investigations on brain structure and cognitive processing have revealed less deficits in schizophrenia patients with comorbid cannabis use (sch + cud) compared to abstinent schizophrenia patients (sch). |
2019-03-25 |
2023-08-13 |
human |
| Thomas Schnell, Karsten Heekeren, Jörg Daumann, Euphrosyne Gouzoulis-Mayfran. Inhibition of return (IOR) in patients with schizophrenia and cannabis use. Progress in neuro-psychopharmacology & biological psychiatry. vol 89. 2019-03-25. PMID:30184467. |
the aim of the present study is to extend previous work by investigating ior functioning in patients with schizophrenia and cannabis use. |
2019-03-25 |
2023-08-13 |
human |
| Thomas Schnell, Karsten Heekeren, Jörg Daumann, Euphrosyne Gouzoulis-Mayfran. Inhibition of return (IOR) in patients with schizophrenia and cannabis use. Progress in neuro-psychopharmacology & biological psychiatry. vol 89. 2019-03-25. PMID:30184467. |
therefore, we compared ior functioning in four groups: 62 patients with schizophrenia and 46 healthy controls, both with and without cannabis use. |
2019-03-25 |
2023-08-13 |
human |
| Celia J A Morgan, Tom P Freeman, Chandni Hindocha, Grainne Schafer, Chelsea Gardner, H Valerie Curra. Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Translational psychiatry. vol 8. issue 1. 2019-03-14. PMID:30185793. |
frequent cannabis users may show a blunted anti- psychotic response to cbd, which is of concern due to the high rates of cannabis use disorders in patients with schizophrenia. |
2019-03-14 |
2023-08-13 |
Not clear |
| Douglas L Boggs, Toral Surti, Aarti Gupta, Swapnil Gupta, Mark Niciu, Brian Pittman, Ashley M Schnakenberg Martin, Halle Thurnauer, Andrew Davies, Deepak C D'Souza, Mohini Ranganatha. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology. vol 235. issue 7. 2019-03-13. PMID:29619533. |
the effects of cannabidiol (cbd) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. |
2019-03-13 |
2023-08-13 |
Not clear |
| Douglas L Boggs, Toral Surti, Aarti Gupta, Swapnil Gupta, Mark Niciu, Brian Pittman, Ashley M Schnakenberg Martin, Halle Thurnauer, Andrew Davies, Deepak C D'Souza, Mohini Ranganatha. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology. vol 235. issue 7. 2019-03-13. PMID:29619533. |
preliminary evidence suggests that cannabidiol (cbd) may be effective in the treatment of neurodegenerative disorders; however, cbd has never been evaluated for the treatment of cognitive impairments associated with schizophrenia (cias). |
2019-03-13 |
2023-08-13 |
Not clear |
| María Bettina Ortiz-Medina, Marta Perea, Julio Torales, Antonio Ventriglio, Giovanna Vitrani, Lourdes Aguilar, Carlos Roncer. Cannabis consumption and psychosis or schizophrenia development. The International journal of social psychiatry. vol 64. issue 7. 2019-03-08. PMID:30442059. |
cannabis consumption and psychosis or schizophrenia development. |
2019-03-08 |
2023-08-13 |
Not clear |